Literature DB >> 29893339

An atypical presentation of POEMS syndrome with IgG kappa type M protein and normal VEGF level: Case report and review of literature.

Swaroopa Pulivarthi1, Murali Krishna Gurram2.   

Abstract

POEMS syndrome is a multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. We present an atypical case of POEMS syndrome with subclinical polyneuropathy, splenomegaly, hypogonadism, and myeloma of immunoglobulin G kappa type. The typical osteosclerotic lesions and skin lesions were absent, and vascular endothelial growth factor (VEGF) level was normal. Our patient also had chronic kidney disease due to focal segmental glomerulosclerosis. The patient died due to multisystem complications nine months after presenting with acute on chronic renal failure. POEMS syndrome is an uncommon, potentially fatal paraneoplastic syndrome presenting with plasma cell neoplasm and multisystem involvement. Despite the normal VEGF level, our patient was diagnosed to have possible POEMS syndrome due to other clinical manifestations. It may be reasonable to expand the diagnostic criteria of POEMS syndrome if further atypical cases are reported in the future.

Entities:  

Keywords:  IgG kappa light chain; POEMS syndrome; renal involvement

Mesh:

Substances:

Year:  2018        PMID: 29893339     DOI: 10.4103/0973-1482.172123

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  2 in total

1.  Heavy metals intoxication in a patient with POEMS-like symptoms: a case report.

Authors:  Jun Hao; Shouxin Li; Yuxue Chen
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

2.  Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.

Authors:  Sho Ikeda; Takahiro Kobayashi; Masaya Saito; Atsushi Komatsuda; Kumi Ubukawa; Yoshihiro Kameoka; Naoto Takahashi
Journal:  Intern Med       Date:  2019-08-06       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.